[go: up one dir, main page]

AU2001236005A1 - Preparations stabilized over long time - Google Patents

Preparations stabilized over long time

Info

Publication number
AU2001236005A1
AU2001236005A1 AU2001236005A AU3600501A AU2001236005A1 AU 2001236005 A1 AU2001236005 A1 AU 2001236005A1 AU 2001236005 A AU2001236005 A AU 2001236005A AU 3600501 A AU3600501 A AU 3600501A AU 2001236005 A1 AU2001236005 A1 AU 2001236005A1
Authority
AU
Australia
Prior art keywords
long time
over long
stabilized over
preparations stabilized
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236005A
Inventor
Akihiko Saito
Yasushi Sato
Tadao Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001236005A1 publication Critical patent/AU2001236005A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2001236005A 2000-02-29 2001-02-28 Preparations stabilized over long time Abandoned AU2001236005A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-53310 2000-02-29
JP2000053310 2000-02-29
PCT/JP2001/001524 WO2001064241A1 (en) 2000-02-29 2001-02-28 Preparations stabilized over long time

Publications (1)

Publication Number Publication Date
AU2001236005A1 true AU2001236005A1 (en) 2001-09-12

Family

ID=18574710

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236005A Abandoned AU2001236005A1 (en) 2000-02-29 2001-02-28 Preparations stabilized over long time

Country Status (5)

Country Link
US (1) US7163671B2 (en)
EP (1) EP1260230A4 (en)
JP (1) JP4683810B2 (en)
AU (1) AU2001236005A1 (en)
WO (1) WO2001064241A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112409B2 (en) * 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
RS51292B (en) * 2000-05-15 2010-12-31 F. Hoffmann-La Roche Ag. NEW PHARMACEUTICAL MIXTURE
CA2417960C (en) 2000-08-04 2012-07-10 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
DE60229961D1 (en) * 2001-08-29 2009-01-02 Chugai Pharmaceutical Co Ltd ANTIBODIES CONTAINING STABILIZED PREPARATIONS
SI21258A (en) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stable pharmaceutical preparation containing erythropoietin and poloxamer polyol
EP1541165A4 (en) * 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Method of stabilizing protein solution preparation
KR20050089857A (en) * 2002-12-26 2005-09-08 아지노모토 가부시키가이샤 Inhibitor for liver cancer onset and progress
EP2537524B1 (en) 2003-05-15 2016-07-06 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
BRPI0411114B8 (en) * 2003-06-10 2021-05-25 Lg Chemical Ltd stable aqueous solution of human erythropoietin, not containing serum albumin
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
WO2008068885A1 (en) * 2006-11-30 2008-06-12 Sanyo Chemical Industries, Ltd. Protecting agent for use in lyophilization and method for production of physiologically active substance
JP5513380B2 (en) * 2007-06-25 2014-06-04 アムジエン・インコーポレーテツド Composition of specific binding agents for hepatocyte growth factor
JP4812807B2 (en) * 2007-06-27 2011-11-09 三洋化成工業株式会社 Protein-containing aqueous solution stabilizer and method for stabilizing protein-containing aqueous solution
UA98001C2 (en) 2007-08-27 2012-04-10 Биодженерикс Аг Liquid formulation of g-csf conjugate
ES2962777T3 (en) * 2007-11-15 2024-03-21 Amgen Inc Antioxidant-stabilized aqueous antibody formulation for parenteral administration
AU2008343052A1 (en) 2007-12-21 2009-07-09 Lyotropic Therapeutics, Inc. Stabilized formulations of peptides and proteins
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
CA2734275A1 (en) * 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
SI3345615T1 (en) 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN103841934A (en) 2011-10-10 2014-06-04 安皮奥制药股份有限公司 Implantable medical devices for enhancing immune tolerance and methods of making and implanting the same
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
CN104350064A (en) 2012-03-14 2015-02-11 耶达研究及发展有限公司 Modified kisspeptin peptides and uses thereof
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
ES2688895T3 (en) * 2013-03-13 2018-11-07 F. Hoffmann-La Roche Ag Formulations with reduced oxidation
AR095399A1 (en) 2013-03-13 2015-10-14 Genentech Inc FORMULATIONS WITH REDUCED OXIDATION, METHOD
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
SG10201707619RA (en) 2013-03-15 2017-10-30 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
WO2016028790A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
AU2016215070B2 (en) * 2015-02-06 2020-09-24 Latitude Pharmaceuticals, Inc. Aqueous solution formulations of vancomycin
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES
UA123679C2 (en) 2016-05-27 2021-05-12 Іпсен Біофарм Лімітед LIQUID NEUROTOXIN COMPOSITION STABILIZED BY TRYPTOPHANE OR TYROSINE
CN119120371A (en) * 2024-11-13 2024-12-13 知佰幸细胞库(浙江)有限公司 Composition for promoting cell regeneration and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56154419A (en) * 1980-04-30 1981-11-30 Green Cross Corp:The Heat treatment of alpha-fetoprotein-containing aqueous solution
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
JP2577742B2 (en) 1986-07-18 1997-02-05 中外製薬株式会社 Stable granulocyte colony-stimulating factor containing preparation
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
JP2577743B2 (en) * 1986-07-18 1997-02-05 中外製薬株式会社 Stable granulocyte colony-stimulating factor containing preparation
JP2577744B2 (en) * 1986-07-18 1997-02-05 中外製薬株式会社 Stable granulocyte colony-stimulating factor containing preparation
JPH02116515A (en) 1988-10-26 1990-05-01 Matsushita Electric Works Ltd Manufacture of inorganic building material
JP2732091B2 (en) 1988-10-31 1998-03-25 キヤノン株式会社 Video signal processing device
JPH0768137B2 (en) * 1989-06-15 1995-07-26 株式会社ミドリ十字 Albumin preparation and manufacturing method thereof
JP2949846B2 (en) * 1990-11-30 1999-09-20 吉富製薬株式会社 How to store albumin preparations
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
JPH0768137A (en) 1993-09-02 1995-03-14 Dow Chem Japan Ltd Separation membrane module
JPH10265404A (en) * 1996-02-02 1998-10-06 Mitsui Chem Inc Pharmaceutical preparation containing human growth hormone
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
JP2000247903A (en) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation

Also Published As

Publication number Publication date
US7163671B2 (en) 2007-01-16
WO2001064241A1 (en) 2001-09-07
JP4683810B2 (en) 2011-05-18
US20030092622A1 (en) 2003-05-15
EP1260230A1 (en) 2002-11-27
EP1260230A4 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
AU2001236005A1 (en) Preparations stabilized over long time
AU2001294192A1 (en) Solid preparations
AU2001277781A1 (en) Stabilized antibody-containing preparations
AU2001232799A1 (en) Protein c derivatives
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001220246A1 (en) Neckphone
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001282607A1 (en) Solution preparations stabilized over long time
AU2001258349A1 (en) Bisacylguanidine
AU8260701A (en) Solution preparations stabilized over long time
AU2001242479A1 (en) Proliposomal encapsulated preparations
AU2001258924A1 (en) Microsatellite-aflp
AU2001240791A1 (en) Sequence
AU2001259450A1 (en) Cytoskeleton-associated proteins
AU2001288102A1 (en) Solid preparations
AU2001246864A1 (en) Hypotensors
AU2001282521A1 (en) OCT preparations
AU2001272427A1 (en) Solid preparations
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001244863A1 (en) Apoptin-associating protein
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001260192A1 (en) Glycinamides
AU2001236058A1 (en) Preparations for chondrogenesis
AU2001278975A1 (en) Alpha-conotoxin peptides